Collateral for a security interest recorded Jan 27, 2022 (Eclipse Business Capital LLC (F/K/A Encina Business Credit, LLC)).
Lapsed Sep 1, 2024 on the fee record · High confidence
20-year base term ends Dec 1, 2037
First maintenance fee unpaid; grace period ended.
Held by Innovus Pharmaceuticals, Inc.
Filed Dec 1, 2017 as application 15/829,798 · Granted Sep 1, 2020
Base term, 20 years from filing
Today
Lapsed Sep 1, 2024
2017
2037
Clock starts
Dec 1, 2017
Dec 1, 2017
No longer in force
Sep 1, 2024
Sep 1, 2024
Granted
Sep 1, 2020
Sep 1, 2020
Term would have run to
Dec 1, 2037
Dec 1, 2037
base term
after the term ends
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
28
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
Its term would have run to Dec 1, 2037: its 20-year base term, with no adjustment for prosecution delay. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 1, 2017, when this application, 15/829,798, was filed | Dec 1, 2037 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | lapsed Sep 1, 2024 | High confidence |
| Computed term end | The steps above, in order | Sep 1, 2024 | High confidence |
This family
| US 10,399,189 | In force Jul 2038 | Jul 2038 |
| Application 62/505,514 | Pending not computed | not computed |
| Application 62/590,756 | Pending not computed | not computed |
| Application 15/829,797 | Abandoned not computed | not computed |
| US 10,758,505 | this patent Sep 2024 | Sep 2024 |
| Application 15/829,799 | Abandoned not computed | not computed |
| US 10,500,199 | Lapsed on the fee record Dec 2023 | Dec 2023 |
| US 10,864,205 | Lapsed on the fee record Dec 2024 | Dec 2024 |
8 of 28 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 29, 2018 Reel 47624, frame 91 | Damaj, Bassam | Innovus Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 27, 2022 Reel 58789, frame 1 | Innovus Pharmaceuticals, Inc.; Semprae Laboratories, Inc. | Eclipse Business Capital LLC (F/K/A Encina Business Credit, LLC), as Agent | Security Interest |
| Feb 10, 2022 Reel 58976, frame 706 | Innovus Pharmaceuticals, Inc. | Avenue Venture Opportunities Fund II, L.P. | Security Interest |
| Jun 14, 2024 Reel 67728, frame 206 | Avenue Venture Opportunities Fund, L.P. | Innovus Pharmaceuticals, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.